OverviewSuggest Edit

Gossamer Bio is a company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Its strategy is to leverage an asset-rich in-licensing environment, with a focus on utilizing a team with a track record of execution in immunology, inflammation, fibrosis and oncology.

TypePublic
Founded2015
HQSan Diego, CA, US
Websitegossamerbio.com

Latest Updates

Employees (est.) (Feb 2019)118(+21%)
Share Price (Sept 2021)$12.3(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Gossamer Bio

Bryan Giraudo

Bryan Giraudo

Chief Financial Officer
Luisa Salter-Cid

Luisa Salter-Cid

Chief Scientific Officer
Kristina Burow

Kristina Burow

Director
Thomas Daniel

Thomas Daniel

Director
Deanna Weber

Deanna Weber

Vice President, Human Resources
Faheem Hasnain

Faheem Hasnain

Co-Founder, Chairman, and Chief Executive Officer
Show more

Gossamer Bio Office Locations

Gossamer Bio has offices in San Diego and Dublin 2
San Diego, CA, US (HQ)
3013 Science Park Rd #200
Dublin 2, IE
Fitzwilliam Hall, Glandore Business Centres, Fitzwilliam Pl
Show all (2)

Gossamer Bio Financials and Metrics

Gossamer Bio Revenue

USD

Net income (Q2, 2021)

(59.8m)

EBIT (Q2, 2021)

(55.6m)

Market capitalization (23-Sept-2021)

922.6m

Closing stock price (23-Sept-2021)

12.3

Cash (30-Jun-2021)

342.5m

EV

610.1m
Gossamer Bio's current market capitalization is $922.6 m.
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

General and administrative expense

83.0k262.0k39.1m49.7m

R&D expense

6.4m143.4m160.9m

Operating expense total

83.0k6.7m182.5m210.6m

EBIT

(83.0k)(6.7m)(186.1m)(234.0m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021

General and administrative expense

8.0m9.7m9.8m10.7m11.7m11.3m11.3m

R&D expense

25.0m35.7m40.1m41.4m38.7m41.8m44.3m

Operating expense total

33.0m45.3m50.0m52.2m50.3m53.2m55.6m

EBIT

(34.0m)(46.3m)(50.0m)(55.0m)(65.3m)(53.2m)(55.6m)
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Cash

60.0k315.0k135.1m486.1m

Prepaid Expenses

130.0k7.5m9.1m

Current Assets

60.0k445.0k409.3m522.3m

PP&E

5.4m5.5m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021

Cash

141.1m170.8m148.5m130.7m111.4m486.1m439.7m342.5m

Prepaid Expenses

1.7m16.6m25.6m5.9m9.3m8.0m12.0m10.5m

Current Assets

258.4m497.8m489.6m452.4m355.4m608.4m465.8m417.0m

PP&E

3.0m4.1m4.8m5.1m5.7m5.8m5.9m5.6m
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Net Income

(83.0k)(6.8m)(180.3m)(243.4m)

Depreciation and Amortization

917.0k1.4m

Accounts Payable

(1.4m)7.0m

Cash From Operating Activities

20.0k(5.7m)(144.8m)(176.4m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021

Net Income

(321.0k)(108.2m)(32.6m)(77.1m)(125.6m)(54.1m)(120.9m)(57.6m)(117.5m)

Depreciation and Amortization

163.0k169.0k374.0k625.0k329.0k679.0k416.0k842.0k

Accounts Payable

2.1m823.0k333.0k1.6m(727.0k)(6.6m)(6.6m)

Cash From Operating Activities

(24.0k)(26.0m)(27.8m)(64.6m)(100.7m)(52.3m)(94.7m)(58.9m)(106.3m)
USDFY, 2016

Financial Leverage

-0.5 x
Show all financial metrics

Gossamer Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Gossamer Bio Online and Social Media Presence

Embed Graph

Gossamer Bio News and Updates

GOSSAMER DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm

NEW YORK, May 20, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company")(NASDAQ:GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

NEW YORK, April 12, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...

GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Gossamer Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

NEW YORK, April 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial...

GOSSAMER DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Gossamer Bio, Inc. To Contact The Firm

NEW YORK, NY - (NewMediaWire) - April 03, 2020 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company")(NASDAQ:GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class act…

Gossamer Bio trading 3% above initial IPO price

Shares of Gossamer Bio, Inc. opened at $19 Friday on the Nasdaq , or 19% above its initial public offering price of $16, before falling back to $16.50, or 3% above the initial IPO price. The first trade crossed at 11:22am Eastern for 762,609 shares. The IPO priced on Thursday evening, with the com…

Gossamer Bio prices IPO

Biotech Gossamer Bio. Inc. , an immunology- and oncology-focused company with six drugs in its pipeline, priced its initial public offering of 17.25 million shares at $16 a share Thursday evening. The sale of the shares will raise about $276 million. Shares are expected to begin trading Friday morni…
Show more

Gossamer Bio Blogs

Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208

Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208 Content Import Mon, 10/11/2021 - 08:36 Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208 …

Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021

Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021 Content Import Thu, 10/07/2021 - 16:02 Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021 October 7, 2021 at 4:01 PM EDT …

Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role

Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role Content Import Tue, 09/21/2021 - 08:32 Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role …

Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update Content Import Mon, 08/09/2021 - 16:02 Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update August 9, 2021 at 4:01 PM EDT This rele…

Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

SAN DIEGO --(BUSINESS WIRE)--Aug. 2, 2021-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report

Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn’s and Colitis Organisation

SAN DIEGO --(BUSINESS WIRE)--Jul. 7, 2021-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will
Show more

Gossamer Bio Frequently Asked Questions

  • When was Gossamer Bio founded?

    Gossamer Bio was founded in 2015.

  • Who are Gossamer Bio key executives?

    Gossamer Bio's key executives are Bryan Giraudo, Luisa Salter-Cid and Kristina Burow.

  • How many employees does Gossamer Bio have?

    Gossamer Bio has 118 employees.

  • Who are Gossamer Bio competitors?

    Competitors of Gossamer Bio include Silverback Therapeutics, Neovii and SQZ Biotech.

  • Where is Gossamer Bio headquarters?

    Gossamer Bio headquarters is located at 3013 Science Park Rd #200, San Diego.

  • Where are Gossamer Bio offices?

    Gossamer Bio has offices in San Diego and Dublin 2.

  • How many offices does Gossamer Bio have?

    Gossamer Bio has 2 offices.